Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury
The Association Between Initial Concentrations of Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury
1 other identifier
observational
99
1 country
1
Brief Summary
After written consent from next-of-kin patients with severe traumatic brain injury was included from the neurointensive care unit (NICU) at Sahlgrenska university hospital, Gothenburg. Blood and CSF samples were collected during the initial 3 weeks after trauma. 1 year after trauma patients were assessed according to Glasgow outcome scale (GOS), NIHSS and Barthels. 10-15 years after trauma a repeated evaluation according to GOS was performed by telephone. Different biomarkers such as Neurofilament light, Glial fibrillary acidic protein and Tau among others, was analyzed from serum and CSF samples. Further patients were explored Apolipoprotein-E genetype (APOE). The investigators hypothesize that higher biomarkers concentrations and positive test for this gene relate to worse outcome 1-year and 10-15 years after trauma. Further that these biomarkers and genetic marker further have prognostic value on outcome 1-year and 10-15 years after trauma. Finally, the investigators want to explore the concentrations dynamics of these biomarkers in serum and CSF in the acute phase after trauma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2000
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2000
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedFirst Submitted
Initial submission to the registry
November 18, 2021
CompletedFirst Posted
Study publicly available on registry
December 1, 2021
CompletedDecember 1, 2021
November 1, 2021
16.2 years
November 18, 2021
November 30, 2021
Conditions
Outcome Measures
Primary Outcomes (4)
In severe traumatic brain injury patient; Correlation of Neurochemical biomarkers analyzed in CSF and serum, assessed in the initial ICU period, correlated to Glasgow Outcome Scale (GOS) at 1 year post-trauma
GOS 1-3 - Poor outcome, GOS 4-5 Good outcome
1 year after trauma
In severe traumatic brain injury patient; Correlation of Neurochemical biomarkers analyzed in CSF and serum, assessed in the initial ICU period, correlated to Glasgow Outcome Scale (GOS) at 10-15 years post-trauma
GOS 1-3 - Poor outcome, GOS 4-5 Good outcome
10-15 years after trauma
In severe traumatic brain injury patient; correlation of the genetic alleles of APOE correlated to Glasgow Outcome Scale (GOS) at 1-year post-trauma)
GOS 1-3 - Poor outcome, GOS 4-5 Good outcome
1 year after trauma
In severe traumatic brain injury patient; correlation of the genetic alleles of APOE correlated to Glasgow Outcome Scale (GOS) at 10-15 years post-trauma)
GOS 1-3 - Poor outcome, GOS 4-5 Good outcome
10-15 years after trauma
Eligibility Criteria
Patient with severe traumatic brain injury, defined by our inclusion criteria, where enrolled from the Neurointensive care unit at Sahlgrenska university hospital, Gothenburg. Sahlgrenska University hospital is a tertiary hospital admitting patients from the whole south west part of Sweden.
You may qualify if:
- Reaction level scale \>3, corresponding to a Glasgow coma scale \<9
- A therapeutic indication for intracranial pressure monitoring
- Need for ventilator treatment
You may not qualify if:
- Not residing in Sweden
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bengt Nellgardlead
- Svenska alzheimerfondencollaborator
- Stroke Foundationcollaborator
Study Sites (1)
Sahlgrenska University Hospital
Mölndal, Västra Götaland County, 431 80, Sweden
Biospecimen
Biomarkers Neurofilament light (NFL) and Glial Fibrillary Acid Protein (GFAP) were analyzed in CSF, TAU in serum, APOE- genotype was explored in whole blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bengt Nellgård, MD PhD Professor
University of Gothenburg and Västra götaland Regionen, Sahlgrenska Universitetssjukhus Mölndal
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 15 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Associate professor
Study Record Dates
First Submitted
November 18, 2021
First Posted
December 1, 2021
Study Start
October 1, 2000
Primary Completion
December 1, 2016
Study Completion
December 1, 2016
Last Updated
December 1, 2021
Record last verified: 2021-11